The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: London Stocks End Lower Ahead Of Bank Stress Tests

Fri, 24th Oct 2014 16:11

LONDON (Alliance News) - The major UK stock indices closed lower Friday as investors took a cautious approach ahead of a weekend that brings the long-awaited results of the European Union bank stress tests. Concerns about the spread of Ebola also gave sentiment a knock after a doctor returning to the US from West Africa was confirmed to have the virus.

The FTSE 100 closed down 0.5% at 6,388.73 and the FTSE 250 down 0.3% at 15,089.55. The AIM All-Share closed fractionally higher at 709.03.

The week as a whole, however, has been a relatively strong one for London stocks, with the FTSE 100 recording its first gain for five weeks, rising 2.6% since Monday.

On Friday, major European markets also suffered losses, with the French CAC 40 falling 0.5%, and the German DAX off 0.6%. After the European close, US stocks are performing a little better, with the DJIA, the S&P 500, and the Nasdaq Composite all up about 0.3%.

The EU Asset Quality Review, or bank stress tests, are due on Sunday. Capital hoarding by the banks ahead of the tests has for months been widely blamed as part of the reason behind a lack of lending in the eurozone. While banks have been working to shore up their balance sheets, the possibility that some have failed the tests has caused some caution in the markets, especially after a report from Bloomberg on Friday that 25 banks indeed have failed. Bloomberg cited a draft communique of the final results.

Further weighing on sentiment Friday, a doctor who recently returned from volunteering in West Africa was being treated in a New York City hospital after he tested positive for the Ebola virus in the first confirmed case in the city, officials said.

Around the time of the European market close, there was some positive Ebola-related news: that the first Dallas nurse to contract the virus in now free of it and going home, according to US health officials.

Also suppressing the appetite for stocks Friday was official data from China overnight that showed a 1.3% slowdown in the housing market in September, with almost all major cities experiencing a fall in prices. Evidence of a slowdown in the Chinese economy almost always has a negative effect on global equity markets. Some analysts calculate that the housing market, and its associated businesses, account for up to 25% of Chinese gross domestic product, so the property slowdown goes a long way to explaining the fall in third quarter Chinese GDP to its lowest level in five years reported earlier this week.

The UK economy grew by 0.7% in the third quarter from the prior quarter, according to the initial estimate of GDP from the Office for National Statistics on Friday. That's a slow-down from the 0.9% growth recorded in the second quarter, but in line with expectations. Year-on-year growth was 3.0%, down from 3.2% in the second quarter, also in line with expectations.

The data did little to boost the stock market, but did provide a small boost to to the pound, which pushed to intra-day highs of USD1.6099 and EUR1.2696.

With the UK economy continuing to outperform other European economies, the EU has asked the UK government to pay an extra EUR2.1 billion towards the EU budget. Remarkably, Greece also has been asked to contribute more, while Germany will receive a rebate, according to the calculations. The request made difficult reading for UK Prime Minister David Cameron, who is seeing growing dissent within his own party over UK membership of the EU, with a number of Conservatives defecting to anti-EU party UKIP.

Within the UK stock movers Friday, Shire ended as the best blue-chip performer after using a midday release to increase its full-year earnings guidance for the third time this year. Shire reported a profit rise in its third quarter that was much better than analysts expected, and reiterated its target of doubling its product sales to USD10 billion by 2020.

Shire has always said it has maintained its business momentum throughout the ultimately doomed takeover talks with US-based AbbVie, and in its first results since being left at the altar earlier this week, the pharmaceutical company raised its non-GAAP earnings per American depositary share growth guidance to the high 30% range. At the time of its interim results the company had guided in the low-to-mid 30% range.

Pearson was the worst FTSE 100 performer, ending down 2.6% after saying Chief Financial Officer Robin Freestone will step down by the end of 2015 to explore other interests, as it eked out a 1% rise in sales in the first nine months of the year at constant currency rates. The publishing company retained its full-year guidance, but analysts said the loss of Freestone will be a knock to business.

Also in the FTSE 100, Tesco closed down another 1.4% at 168.75p Friday after JP Morgan published a negative note on the troubled supermarket, cutting its price target on the stock to 145p from 165p, while reiterating an Underweight rating. The pessimistic note comes after Tesco on Thursday confirmed the error in its first half accounts was bigger than initially thought.

FTSE 250 bank TSB Group gained 1.6%, after reporting a solid set of third quarter results. TSB said it made a GBP33.1 million pretax profit in the third quarter, up from GBP25.7 million in the previous three months. There was no consensus expectations for the quarterly results, but Jefferies said it would categorise the numbers as "fine". Shares in Lloyds Banking Group, which still owns 50% of TSB, gained 0.7%.

Spectris was the best mid-cap performer, however, gaining 4.4% despite saying its full-year results will be a little below consensus. The instrumentation and controls company said sales in its third quarter to end-September fell 5%, as growth contributed by acquisitions of 2% was offset by the strength of sterling, which had a negative effect of 7%. Jefferies said that a heavy share price fall in recent months had priced in an even-worse outcome, and the actual result was better than feared.

Pets At Home ended up 3.5% after reporting sales growth of 4.2% in both the second quarter and first half, in line with expectations.

Hikma Pharmaceuticals was the worst FTSE 250 performer, down 5.6%, after saying it received a warning letter from the US Food and Drug Administration related to a March inspection of its manufacturing facility in Portugal, although it stressed it does not believe this will impact its financial guidance for the full year. In the letter, the FDA raised issues related to investigations and environmental monitoring at the the facility, Hikma said.

The early focus of the markets on Monday is likely to be any upsets revealed over the weekend by the EU bank stress tests. Outside of that, the German October IFO business climate survey will be released in the morning, and there is US October PMI data in the afternoon.

APR Energy is scheduled to provide an interim management statement.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
22 Feb 2024 09:42

TOP NEWS: Hikma boosts dividend after year of "significant progress"

(Alliance News) - Shares in Hikma Pharmaceuticals PLC jumped on Thursday after it lifted the dividend by 29% amid better-than-expected annual profit.

Read more
22 Feb 2024 07:51

Hikma lifts dividend after double-digit growth in 2023

(Sharecast News) - Hikma Pharmaceuticals impressed the market with its annual results on Thursday as it bumped up its dividend by almost a third following double-digit growth in core revenues and profits in 2023.

Read more
15 Feb 2024 14:42

UK earnings, trading statements calendar - next 7 days

Friday 16 February 
NatWest Group PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 19 February 
Bank of Cyprus Holdings PLCFull Year Results
MoneySupermarket.com PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 20 February 
Antofagasta PLCFull Year Results
Barclays PLCFull Year Results
BHP Group LtdHalf Year Results
Coca-Cola Europacific Partners PLCFull Year Results
Gran Tierra Energy IncFull Year Results
InterContinental Hotels Group PLCFull Year Results
Petra Diamonds LtdHalf Year Results
Springfield Properties PLCHalf Year Results
Wednesday 21 February 
BAE Systems PLCFull Year Results
Conduit Holdings LtdFull Year Results
Glencore PLCFull Year Results
HSBC Holdings PLCFull Year Results
Rio Tinto PLCFull Year Results
Riverstone Credit Opportunities Income PLCFull Year Results
Tate & Lyle PLCTrading Statement
Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
2 Feb 2024 07:23

Hikma agrees to settle US opioid claims

(Sharecast News) - Hikma Pharmaceuticals announced an agreement in principle to address the majority of opioid-related claims filed against it by various US states, local communities and tribal nations on Friday.

Read more
1 Feb 2024 20:00

EARNINGS AND TRADING: Tandem FY sales down 17%; Hikma's opioid deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 09:29

LONDON BROKER RATINGS: Berenberg cuts target prices for miners

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Wednesday:

Read more
20 Dec 2023 09:25

LONDON BROKER RATINGS: UBS cuts DS Smith; Kepler likes Genus

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
19 Dec 2023 09:11

LONDON BROKER RATINGS: Peel Hunt raises Flutter to 'buy' from 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
7 Nov 2023 13:08

Jefferies downgrades Hikma to 'hold'

(Sharecast News) - Jefferies downgraded Hikma Pharmaceuticals on Tuesday to 'hold' from 'buy' and cut the price target to 1,940p from 2,125p.

Read more
7 Nov 2023 09:28

LONDON BROKER RATINGS: Watches of Switzerland impresses HSBC; Asos cut

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
7 Nov 2023 07:43

LONDON BRIEFING: AB Foods hails Primark; Beazley premiums rise

(Alliance News) - London's FTSE 100 is called to open in the red on Tuesday, following Asian equities lower, as the good feeling in equity markets after the softer US jobs data on Friday gives way to some caution.

Read more
6 Nov 2023 12:01

Berenberg stays at 'hold' on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg reiterated their 'hold' rating and 2,100.0p target price on Hikma Pharmaceuticals on Monday, saying a "lighter" second half was playing out in its injectables unit.

Read more
3 Nov 2023 09:31

LONDON BROKER RATINGS: JPMorgan lifts Smith & Nephew

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
2 Nov 2023 15:12

London close: Stocks rise as BoE keeps rates steady

(Sharecast News) - London's stock markets ended the day on a positive note on Thursday, following the Bank of England's decision to maintain interest rates as markets widely expected.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.